Sugi Predict

Sugi Predict / Compounds / SCHEMBL1509845

SCHEMBL1509845

SCHEMBL1509845

CC(C)(C)OC(=O)NCCCOCCOCCOCCCNC(=O)CCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.49
▸ CA1 P00915 8/20 0.45
▸ CA2 P00918 8/20 0.45
▸ CA12 O43570 5/20 0.45
▸ CA9 Q16790 5/20 0.45
▸ MAOA P21397 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ EPHX1 P07099 1/20 0.42
▸ TSHR P16473 1/20 0.41
▸ CYP3A4 P08684 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1509910 0.97 MEN1 (0.50) MEN1GAAKMT2ATDP1CA1
SCHEMBL13968020 0.93 MEN1 (0.49) MEN1GAAKMT2ATDP1CA1
SCHEMBL1509861 0.91 MEN1 (0.45) MEN1GAAKMT2ATDP1CA1
SCHEMBL18484173 0.90 TSHR (0.53) MEN1GAAKMT2ATDP1CA1
SCHEMBL4388456 0.90 MEN1 (0.46) MEN1GAAKMT2ATDP1CA1
SCHEMBL20288400 0.89 MEN1 (0.40) MEN1GAAKMT2ATDP1CA1
SCHEMBL24983130 0.89 MEN1 (0.48) MEN1GAAKMT2ATDP1CA1
SCHEMBL7745994 0.89 TDP1 (0.49) MEN1GAAKMT2ATDP1CA1
SCHEMBL4394882 0.88 MEN1 (0.53) MEN1GAAKMT2ATDP1CA1
SCHEMBL12341824 0.87 TDP1 (0.50) MEN1GAAKMT2ATDP1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572795-A2 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS The University of Chicago (US) 2025-06-25 — — EP disclosed
US-20250114441-A1 POLYMERIC VACCINE FOR OPIOID ADDICTION THE JOHNS HOPKINS UNVERSITY 2025-04-10 — — US disclosed
WO-2024040169-A2 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS THE UNIVERSITY OF CHICAGO (US) 2024-02-22 — — WO disclosed
WO-2023049816-A9 BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF FLAGSHIP PIONEERING, INC. (US) 2023-04-27 — — WO disclosed
CN-115916219-A Bifunctional molecules and methods of use thereof 旗舰创业股份有限公司 2023-04-04 — — CN disclosed
WO-2023049816-A2 BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF FLAGSHIP PIONEERING, INC. (US) 2023-03-30 — — WO disclosed
EP-4138857-A1 BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF Flagship Pioneering, Inc. (US) 2023-03-01 — — EP disclosed
EP-4138858-A1 BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF Flagship Pioneering, Inc. (US) 2023-03-01 — — EP disclosed
EP-4126063-A1 BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF Flagship Pioneering, Inc. (US) 2023-02-08 — — EP disclosed
CN-108770357-B Polymer conjugate vaccines 芝加哥大学 2022-10-28 — — CN disclosed
US-20020061909-A1 Vitronectin receptor antagonist pharmaceuticals LANTHEUS MI REAL ESTATE, LLC 2002-05-23 — — US disclosed
US-20020041878-A1 Vitronectin receptor antagonist pharmaceuticals LANTHEUS MEDICAL IMAGING, INC. 2002-04-11 — — US disclosed
US-20020015680-A1 QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS CITIZENS BANK, N.A. 2002-02-07 — — US disclosed
US-20020001566-A1 PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-01-03 — — US disclosed
WO-2001097860-A2 PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS FOR USE IN COMBINATION THERAPY BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-12-27 — — WO disclosed
WO-2001097848-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-12-27 — — WO disclosed
EP-1140204-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS Du Pont Pharmaceuticals Company (US) 2001-10-10 — — EP disclosed
EP-1068224-A2 PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS Du Pont Pharmaceuticals Company (US) 2001-01-17 — — EP disclosed
WO-2000035492-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 — — WO disclosed
WO-1999058162-A2 PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS DU PONT PHARMACEUTICALS COMPANY (US) 1999-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020015680-A1 QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS ADGRF1, QRFPR, ADGRE5 MEN1 698/4885GAA 3206/4885KMT2A 4563/4885
US-20020041878-A1 Vitronectin receptor antagonist pharmaceuticals ADGRF1, RXFP1, VCAM1 MEN1 1114/4885GAA 3864/4885KMT2A 4815/4885
US-20020001566-A1 PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS VEGFA, FLT4, FLT1 MEN1 2056/4885GAA 622/4885KMT2A 4507/4885
US-20020061909-A1 Vitronectin receptor antagonist pharmaceuticals ADGRF1, RXFP1, VCAM1 MEN1 1110/4885GAA 3819/4885KMT2A 4836/4885
US-20250114441-A1 POLYMERIC VACCINE FOR OPIOID ADDICTION OPRM1, OPRK1, OPRL1 MEN1 4823/4885GAA 2425/4885KMT2A 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.